Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer

被引:1
|
作者
Wang, Sen [1 ,2 ]
Zhang, Yangyang [1 ,2 ]
Chen, Guangyu [3 ,4 ]
Zhao, Peng [1 ,2 ]
Wang, Xiaoming [1 ,2 ]
Xu, Benling [3 ,4 ,5 ]
Yuan, Long [1 ,2 ,5 ]
机构
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Dept Surg, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Dept Immunotherapy, Zhengzhou, Peoples R China
[5] Henan Canc Hosp, 127 Dongming Rd, Zhengzhou, Henan, Peoples R China
关键词
Colorectal cancer; CXCR3; PD-1; T cell; Immunotherapy; TIM-3;
D O I
10.1016/j.intimp.2024.111988
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: Clinical application of immunotherapy represented by Programmed Death -1 (PD -1) monoclonal antibody has changed the treatment paradigm for colorectal cancer (CRC), and tumor -infiltrating T lymphocytes are critical for anti -PD -1 therapy in CRC. However, there are few studies on the relationship between the expression CXCR3 on T lymphocytes and the clinical aspects of CRC. In this study, we analyzed the expression levels of CXCR3 and PD -1 in CD8 + and CD4 + T lymphocytes in healthy donors (HDs) and patients with CRC. Methods: We detected the expressions of CXCR3 and PD -1 on T lymphocytes in peripheral blood of healthy donors as well as peripheral blood, tumor tissue and para -cancerous tissues of patients with CRC using flow cytometry. We also analyzed the relationship between the expressions of CXCR3 and PD -1 on T lymphocytes and the pathological characteristics of CRC using t test . Results: Expression of CXCR3 on tumor -infiltrating T lymphocytes was lower, whereas the expression of PD -1 was higher than that on para -cancerous tissues and PB in patients with CRC. In patients with lymph node metastasis of CRC, the expressions levels of CXCR3 + PD -1 + on tumor -infiltrating CD8 + and CD4 + T lymphocytes were higher than those in patients without lymph node metastasis. The levels of CXCR3 + PD -1 + expressions differed depending on the primary tumor site. Conclusion: Expressions of CXCR3 and PD -1 on tumor -infiltrating T lymphocytes are related to the development of CRC and metastasis, providing clues for exploring the pathogenesis of CRC and developing new strategies for tumor immunotherapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
    Shogo Kumagai
    Yosuke Togashi
    Takahiro Kamada
    Eri Sugiyama
    Hitomi Nishinakamura
    Yoshiko Takeuchi
    Kochin Vitaly
    Kota Itahashi
    Yuka Maeda
    Shigeyuki Matsui
    Takuma Shibahara
    Yasuho Yamashita
    Takuma Irie
    Ayaka Tsuge
    Shota Fukuoka
    Akihito Kawazoe
    Hibiki Udagawa
    Keisuke Kirita
    Keiju Aokage
    Genichiro Ishii
    Takeshi Kuwata
    Kenta Nakama
    Masahito Kawazu
    Toshihide Ueno
    Naoya Yamazaki
    Koichi Goto
    Masahiro Tsuboi
    Hiroyuki Mano
    Toshihiko Doi
    Kohei Shitara
    Hiroyoshi Nishikawa
    Nature Immunology, 2020, 21 : 1346 - 1358
  • [22] PD-1 signaling in primary T cells
    Riley, James L.
    IMMUNOLOGICAL REVIEWS, 2009, 229 : 114 - 125
  • [23] Role of CXCR3 signaling in response to anti-PD-1 therapy
    Han, Xiao
    Wang, Ying
    Sun, Jing
    Tan, Tao
    Cai, Xiaomin
    Lin, Peinan
    Tan, Yang
    Zheng, Bingfeng
    Wang, Biao
    Wang, Jiawei
    Xu, Lingyan
    Yu, Zhengyi
    Xu, Qiang
    Wu, Xingxin
    Gu, Yanhong
    EBIOMEDICINE, 2019, 48 : 169 - 177
  • [24] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
    Kumagai, Shogo
    Togashi, Yosuke
    Kamada, Takahiro
    Sugiyama, Eri
    Nishinakamura, Hitomi
    Takeuchi, Yoshiko
    Vitaly, Kochin
    Itahashi, Kota
    Maeda, Yuka
    Matsui, Shigeyuki
    Shibahara, Takuma
    Yamashita, Yasuho
    Irie, Takuma
    Tsuge, Ayaka
    Fukuoka, Shota
    Kawazoe, Akihito
    Udagawa, Hibiki
    Kirita, Keisuke
    Aokage, Keiju
    Ishii, Genichiro
    Kuwata, Takeshi
    Nakama, Kenta
    Kawazu, Masahito
    Ueno, Toshihide
    Yamazaki, Naoya
    Goto, Koichi
    Tsuboi, Masahiro
    Mano, Hiroyuki
    Doi, Toshihiko
    Shitara, Kohei
    Nishikawa, Hiroyoshi
    NATURE IMMUNOLOGY, 2020, 21 (11) : 1346 - +
  • [26] Complement-Opsonized HIV-1 Alters Cross Talk Between Dendritic Cells and Natural Killer (NK) Cells to Inhibit NK Killing and to Upregulate PD-1, CXCR3, and CCR4 on T Cells
    Ellegard, Rada
    Khalid, Mohammad
    Svanberg, Cecilia
    Holgersson, Hanna
    Thoren, Ylva
    Wittgren, Mirja Karolina
    Hinkula, Jorma
    Nystrom, Sofia
    Shankar, Esaki M.
    Larsson, Marie
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [27] Potential role of CXCR3 in proliferation and invasion of prostate cancer cells
    Shen, Daqing
    Cao, Xianxiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (07): : 8091 - 8098
  • [28] PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
    Kamada, Takahiro
    Togashi, Yosuke
    Tay, Christopher
    Ha, Danbee
    Sasaki, Akinori
    Nakamura, Yoshiaki
    Sato, Eiichi
    Fukuoka, Shota
    Tada, Yasuko
    Tanaka, Atsushi
    Morikawa, Hiromasa
    Kawazoe, Akihito
    Kinoshita, Takahiro
    Shitara, Kohei
    Sakaguchi, Shimon
    Nishikawa, Hiroyoshi
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (20) : 9999 - 10008
  • [29] A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells
    Barati, Mehdi
    Mirzavi, Farshad
    Atabaki, Mahdi
    Bibak, Bahram
    Mohammadi, Mojgan
    Jaafari, Mahmoud Reza
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 111
  • [30] SERUM CXCR3 CD4+T CELLS AND CXCR3 EXPRESSION IN RENAL TISSUES OF PEDIATRIC SYSYTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Ibrahim, Magid Aa Fattah
    El-Sayed, Shereen S.
    Said, Ragia M.
    Ahmed, Naglaa S.
    Ismail, Mona A.
    Radwan, Nesrine M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34